Episode Details
Back to Episodes
AI Neuroimaging Growth & Margin Expansion Ahead | IXICO plc (IXI) | The Watchlist E39
Description
In this episode of The Watchlist, IXICO plc (LSE: IXI) shares its latest financial results and expanding role in AI-powered neuroimaging for major pharma and biotech partners. CEO Bram Goorden explains how the company is scaling its technology, building margin expansion into its model, and focusing on high-value neurological disease areas such as Alzheimer's, Parkinson's, and rare CNS disorders.
Listeners will hear:
• How IXICO is achieving double-digit revenue growth
• The role of AI imaging in supporting global drug development
• Margin expansion opportunities over the next 12–24 months
• Why IXICO leads in CNS-focused neuroimaging
• Key markets and therapeutic areas shaping future growth
Website: https://ixico.com
Disclaimer: This podcast is made in partnership with IXICO plc. This podcast is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://themarketonline.ca/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.